The Institute for the Study of War’s October 30 assessment depicts a Russian campaign that is increasingly defined by long-range strikes, coercive pressure on civilians, and incremental battlefield gains rather than decisive operational breakthroughs. With front-line movement still limited, Moscow appears to be leaning on attritional warfare to sap Ukraine’s air defenses, logistics, and public resilience.
A new astronomical map of so-called empty space is challenging the long-held view of the Milky Way as a relatively calm environment between stars. The findings suggest that the galaxy’s low-density regions are more structured, dynamic and influential than previously assumed, with implications for how scientists model star formation, cosmic rays and the movement of matter across the galaxy.
Ars staff members are remembering Patrick Stewart not only as a singular screen presence, but as an actor whose portrayal of Jean-Luc Picard helped define an era of science fiction and technology culture. Their reflections underscore how deeply the character resonated with audiences far beyond entertainment, shaping the way many people imagine leadership, intellect, and moral clarity.
Ollie, an AI assistant built around a privacy-first promise, is shutting down in one week, according to its founder. The closure underscores the mounting pressure on smaller AI products as the assistant market becomes increasingly crowded and capital-intensive.
McDonald’s has been dealt a legal setback after a U.S. judge allowed a class-action lawsuit over the McRib sandwich to proceed, according to court reporting. The case alleges the fast-food chain misled consumers by marketing the product as containing rib meat when, plaintiffs argue, it does not. The ruling does not decide the merits of the claims, but it keeps the dispute alive and raises fresh scrutiny over food labeling and marketing claims in the packaged and quick-service restaurant sectors.
A new global report points to a sharp rise in anorexia nervosa and bulimia nervosa between 1990 and 2023, intensifying concern among clinicians that the rapid spread of GLP-1 weight-loss drugs could worsen eating-disorder risk in vulnerable patients. While the medicines have transformed obesity treatment, experts warn that their appetite-suppressing effects may complicate screening, monitoring and long-term mental health care.